Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13489802 | 0.93 | ADORA1 (0.48) | L3MBTL1ADORA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL10691207 | 0.89 | ADORA1 (0.46) | L3MBTL1ADORA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL126159 | 0.89 | RAB9A (0.68) | MEN1KMT2ARAB9ASMN1; SMN2POLB | |
| SCHEMBL30485981 | 0.89 | RAB9A (0.68) | MEN1KMT2ARAB9ASMN1; SMN2POLB | |
| SCHEMBL19718960 | 0.89 | ADORA1 (0.48) | L3MBTL1ADORA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3211414 | 0.87 | XIAP (0.59) | L3MBTL1ADORA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29581363 | 0.87 | GRM5 (0.51) | L3MBTL1ADORA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3883249 | 0.87 | FFAR2 (0.48) | L3MBTL1ADORA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL31038670 | 0.87 | ALDH1A1 (0.54) | L3MBTL1ADORA1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL968790 | 0.87 | GRM5 (0.51) | L3MBTL1ADORA1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294491-A1 | SALT OF HETEROCYCLIC COMPOUND WITH ANTI-MALARIA ACTIVITY, AND CRYSTALS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-09-05 | — | — | US | disclosed |
| EP-4342889-A1 | SALT OF HETEROCYCLIC COMPOUND WITH ANTI-MALARIA ACTIVITY, AND CRYSTALS THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2024-03-27 | — | — | EP | disclosed |
| US-20230108442-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-04-06 | — | — | US | disclosed |
| US-20230108442-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-04-06 | — | — | US | disclosed |
| WO-2023002965-A1 | SALT OF HETEROCYCLIC COMPOUND WITH ANTI-MALARIA ACTIVITY, AND CRYSTALS THEREOF | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002965-A1 | SALT OF HETEROCYCLIC COMPOUND WITH ANTI-MALARIA ACTIVITY, AND CRYSTALS THEREOF | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2023-01-26 | — | — | WO | disclosed |
| EP-4058147-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd (JP) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021149692-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021149692-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-07-29 | — | — | WO | disclosed |
| US-20110009454-A1 | COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2004-07-01 | — | — | US | disclosed |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
| WO-2004026869-A1 | IMIDAZOPYRIDINE COMPUNDS AS 5-HT4 RECEPTOR AGONISTS | PFIZER JAPAN INC. (JP) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026869-A1 | IMIDAZOPYRIDINE COMPUNDS AS 5-HT4 RECEPTOR AGONISTS | PFIZER JAPAN INC. (JP) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026868-A1 | N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026868-A1 | N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2004-04-01 | — | — | WO | disclosed |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | UCHIDA CHIKARA (JP) | 2004-02-19 | — | — | US | disclosed |
| US-6624162-B2 | 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. | PFIZER INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003035649-A1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | L3MBTL1 3834/4885ADORA1 175/4885CYP1A2 1205/4885 |
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | L3MBTL1 4579/4885ADORA1 291/4885CYP1A2 782/4885 |
| US-20230108442-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | QDPR, DHODH, THPO | L3MBTL1 4316/4885ADORA1 2435/4885CYP1A2 2750/4885 |
| US-20240294491-A1 | SALT OF HETEROCYCLIC COMPOUND WITH ANTI-MALARIA ACTIVITY, AND CRYSTALS THEREOF | REN, RCC1, LSS | L3MBTL1 4404/4885ADORA1 4139/4885CYP1A2 1411/4885 |
| US-20110009454-A1 | COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS | WIZ, TST, NAT1 | L3MBTL1 1292/4885ADORA1 3433/4885CYP1A2 2625/4885 |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | HTR4, GPR4, HRH4 | L3MBTL1 3511/4885ADORA1 235/4885CYP1A2 851/4885 |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HRH4, HTR4, HRH2 | L3MBTL1 3664/4885ADORA1 158/4885CYP1A2 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.